Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver

Targeting the Kv1.3 potassium channel has proven effective in reducing obesity and the severity of animal models of autoimmune disease. Stichodactyla toxin (ShK), isolated from the sea anemone Stichodactyla helianthus, is a potent blocker of Kv1.3. Several of its analogs are some of the most potent and selective blockers of this channel. However, like most biologics, ShK and its analogs require injections for their delivery, and repeated injections reduce patient compliance during the treatment of chronic diseases. We hypothesized that inducing the expression of an ShK analog by hepatocytes would remove the requirement for frequent injections and lead to a sustained level of Kv1.3 blocker in the circulation. To this goal, we tested the ability of Adeno-Associated Virus (AAV)8 vectors to target hepatocytes for expressing the ShK analog, ShK-235 (AAV-ShK-235) in rodents. We designed AAV8 vectors expressing the target transgene, ShK-235, or Enhanced Green fluorescent protein (EGFP). Transduction of mouse livers led to the production of sufficient levels of functional ShK-235 in the serum from AAV-ShK-235 single-injected mice to block Kv1.3 channels. However, AAV-ShK-235 therapy was not effective in reducing high-fat diet-induced obesity in mice. In addition, injection of even high doses of AAV8-ShK-235 to rats resulted in a very low liver transduction efficiency and failed to reduce inflammation in a well-established rat model of delayed-type hypersensitivity. In conclusion, the AAV8-based delivery of ShK-235 was highly effective in inducing the secretion of functional Kv1.3-blocking peptide in mouse, but not rat, hepatocytes yet did not reduce obesity in mice fed a high-fat diet.

[1]  R. Britton,et al.  A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis , 2022, bioRxiv.

[2]  Yuxiao Tang,et al.  Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  J. Ng,et al.  Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies , 2021, Frontiers in Immunology.

[4]  C. Borchers,et al.  Depletion of essential isoprenoids and ER stress induction following acute liver-specific deletion of HMG-CoA reductase , 2020, Journal of Lipid Research.

[5]  S. Grant,et al.  Olfactory bulb‐targeted quantum dot (QD) bioconjugate and Kv1.3 blocking peptide improve metabolic health in obese male mice , 2020, Journal of neurochemistry.

[6]  Mingyao Li,et al.  Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology. , 2020, Human gene therapy.

[7]  K. Boye,et al.  Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study , 2020, Diabetes, obesity & metabolism.

[8]  S. S. St Martin,et al.  AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction , 2020, Molecular therapy. Methods & clinical development.

[9]  H. Büning,et al.  Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives , 2020, Cancers.

[10]  J. Mendell,et al.  Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy , 2020, JAMA neurology.

[11]  K. Chandy,et al.  Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin. , 2020, ACS pharmacology & translational science.

[12]  G. Kinsella,et al.  Development of a selective inhibitor for Kv1.1 channels prevalent in demyelinated nerves. , 2020, Bioorganic chemistry.

[13]  M. Laffan,et al.  Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. , 2020, The New England journal of medicine.

[14]  S. Pipe,et al.  First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A , 2019, Blood.

[15]  M. Farzan,et al.  A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo , 2019, Nature Biotechnology.

[16]  B. Schweighardt,et al.  The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy , 2019, Molecular therapy. Methods & clinical development.

[17]  R. Herzog,et al.  Update on clinical gene therapy for hemophilia. , 2019, Blood.

[18]  P. Gulko,et al.  KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis , 2019, Arthritis Research & Therapy.

[19]  P. Bosma,et al.  Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome , 2018, Molecular therapy. Methods & clinical development.

[20]  Ciaran M. Lee,et al.  A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing , 2018, Molecular therapy. Methods & clinical development.

[21]  M. Farzan,et al.  Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  S. Bunting,et al.  Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  C. Beeton,et al.  Differences in ion channel phenotype and function between humans and animal models. , 2018, Frontiers in bioscience.

[24]  Jürgen Hubbuch,et al.  Downstream process development strategies for effective bioprocesses: Trends, progress, and combinatorial approaches , 2017, Engineering in life sciences.

[25]  H. Ertl.  Preclinical models to assess the immunogenicity of AAV vectors. , 2017, Cellular immunology.

[26]  S. Galimberti,et al.  Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI , 2017, Molecular therapy. Methods & clinical development.

[27]  E. Muñoz-Elías,et al.  Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial , 2017, PloS one.

[28]  J. Charli,et al.  The Kv1.3 channel blocker Vm24 enhances muscle glucose transporter 4 mobilization but does not reduce body‐weight gain in diet‐induced obese male rats , 2017, Life sciences.

[29]  R. Norton,et al.  Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. , 2017, Clinical immunology.

[30]  W. Strohl,et al.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy , 2017, BioDrugs.

[31]  K. Chandy,et al.  Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease. , 2017, Current opinion in chemical biology.

[32]  L. Kattenhorn,et al.  Adeno-Associated Virus Gene Therapy for Liver Disease , 2016, Human gene therapy.

[33]  V. Arruda,et al.  AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. , 2015, Blood.

[34]  R. Norton,et al.  Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK , 2015, Marine drugs.

[35]  A. Casellas,et al.  AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease , 2014, Molecular therapy. Methods & clinical development.

[36]  P. Hotez,et al.  Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Songtao Li,et al.  Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease , 2014, Molecular therapy. Methods & clinical development.

[38]  R. Norton,et al.  A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases , 2014, Scientific Reports.

[39]  G. Gao,et al.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue , 2014, Expert opinion on drug delivery.

[40]  P. Bosma,et al.  In the rat liver, Adenoviral gene transfer efficiency is comparable to AAV , 2013, Gene Therapy.

[41]  A. Cavalli,et al.  A Potent and Selective Peptide Blocker of the Kv1.3 Channel: Prediction from Free-Energy Simulations and Experimental Confirmation , 2013, PloS one.

[42]  S. Griffey,et al.  Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance , 2013, Proceedings of the National Academy of Sciences.

[43]  P. Fagone,et al.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. , 2013, Blood.

[44]  T. Conlon,et al.  Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. , 2013, Human gene therapy.

[45]  D. Rader,et al.  Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism. , 2013, Methods in molecular biology.

[46]  W. Chuang,et al.  Recombinant Expression of Margatoxin and Agitoxin-2 in Pichia pastoris: An Efficient Method for Production of KV1.3 Channel Blockers , 2012, PloS one.

[47]  R. Norton,et al.  A C‐terminally amidated analogue of ShK is a potent and selective blocker of the voltage‐gated potassium channel Kv1.3 , 2012, FEBS letters.

[48]  Y. Rosenstein,et al.  Vm24, a Natural Immunosuppressive Peptide, Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells , 2012, Molecular Pharmacology.

[49]  K. Tucker,et al.  Diet‐Induced Obesity Resistance of Kv1.3−/− Mice is Olfactory Bulb Dependent , 2012, Journal of neuroendocrinology.

[50]  K. Chandy,et al.  Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.

[51]  K. Chandy,et al.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. , 2012, Toxicon : official journal of the International Society on Toxinology.

[52]  R. Norton,et al.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. , 2011, Inflammation & allergy drug targets.

[53]  A. Tessitore,et al.  Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  D. Aubert,et al.  Transient expression of genes delivered to newborn rat liver using recombinant adeno‐associated virus 2/8 vectors , 2009, The journal of gene medicine.

[55]  K. Chandy,et al.  Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. , 2008, Immunity.

[56]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  K. Chandy,et al.  Induction and monitoring of active delayed type hypersensitivity (DTH) in rats. , 2007, Journal of visualized experiments : JoVE.

[58]  R. Hajjar,et al.  Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo , 2007, Gene Therapy.

[59]  S. Griffey,et al.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases , 2006, Proceedings of the National Academy of Sciences.

[60]  P. Bosma,et al.  Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  Christine Beeton,et al.  Potassium Channels, Memory T Cells, and Multiple Sclerosis , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[62]  P. Calabresi,et al.  Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases , 2005, Molecular Pharmacology.

[63]  A. Davidoff,et al.  Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. , 2003, Blood.

[64]  L. Kaczmarek,et al.  The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. , 2003, Human molecular genetics.

[65]  P. Giraud,et al.  Selective Blocking of Voltage-Gated K+ Channels Improves Experimental Autoimmune Encephalomyelitis and Inhibits T Cell Activation1 , 2001, The Journal of Immunology.

[66]  H Rauer,et al.  Structural Conservation of the Pores of Calcium-activated and Voltage-gated Potassium Channels Determined by a Sea Anemone Toxin* , 1999, The Journal of Biological Chemistry.

[67]  I. Khaytin,et al.  An essential binding surface for ShK toxin interaction with rat brain potassium channels. , 1996, Biochemistry.

[68]  I. Khaytin,et al.  Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain. , 1996, Biochemical and biophysical research communications.

[69]  I. Khaytin,et al.  Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. , 2009, International journal of peptide and protein research.

[70]  C. Wernstedt,et al.  Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. , 1995, Toxicon : official journal of the International Society on Toxinology.

[71]  G A Gutman,et al.  Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. , 1994, Molecular pharmacology.

[72]  T. Kooistra,et al.  In vitro studies on origin and site of action of enzyme activity responsible for conversion of human proapoprotein A‐I into apoprotein A‐I , 1984, FEBS letters.

[73]  JoVE Video Dataset , 2022 .